rs2069705 — IFNG IFNG Promoter -1616C/T

Upstream regulatory variant ~1,616 bp before the IFNG transcription start site that modulates IFN-gamma expression; the G allele (coding C) is associated with reduced Th1-mediated IFN-gamma output, favouring a Th2-skewed immune balance that increases susceptibility to atopic disease, while the A allele (coding T) supports robust STAT4-driven IFN-gamma transcription and a more Th1-balanced immune response.

Moderate Risk Factor Share

Details

Gene: IFNG
Chromosome: 12
Risk allele: G
Clinical: Risk Factor
Evidence: Moderate

Population Frequency

27%

50%

23%

External

SNPedia ClinVar dbSNP

See your personal result for IFNG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IFNG Promoter -1616C/T — The Th1 Output Dial and Atopic Susceptibility

IFN-gamma¹¹ IFN-gamma
interferon-gamma (IFNG) — the master cytokine of Th1 immunity, produced primarily by CD4+ Th1 cells, CD8+ cytotoxic T cells, and NK cells. It activates macrophages to kill intracellular pathogens, promotes Th1 differentiation, and critically suppresses Th2 cytokines (IL-4, IL-5, IL-13) that drive allergic inflammation is the cornerstone of type 1 adaptive immunity. When IFN-gamma production is robust, T cells preferentially differentiate into the Th1 lineage, suppressing the IgE-producing, eosinophil-recruiting Th2 responses that underlie atopic dermatitis, allergic rhinitis, and asthma. When IFN-gamma output is reduced, the Th1/Th2 balance tips toward Th2 dominance — the molecular underpinning of atopic disease. rs2069705 sits approximately 1,616 base pairs upstream of the IFNG transcription start site (GRCh38 chr12:68161231), in the promoter region that governs how strongly the gene is switched on in response to immune stimuli.

The Mechanism

rs2069705 is annotated as a regulatory variant in the IFNG upstream promoter region. The IFNG gene sits on the minus strand of chromosome 12; papers using coding-strand notation call this position -1616C/T (where C on the coding strand corresponds to the G GRCh38 reference allele on the plus strand, and T corresponds to the A alternate allele). The A allele (coding T) creates or strengthens a binding site for STAT4²² STAT4
Signal Transducer and Activator of Transcription 4 — a transcription factor activated by IL-12 and IL-18 signaling that drives Th1 differentiation and promotes IFN-gamma transcription. A 2024 functional study by Chen et al. demonstrated that rs2069705 "boosts IFNγ transcription by promoting interaction between its promoter and STAT4," activating the downstream JAK/STAT1 pathway. The G allele (coding C) lacks this STAT4 binding enhancement, resulting in lower baseline IFN-gamma transcriptional output — translating to a reduced Th1 tone and a permissive environment for Th2-mediated allergic inflammation.

This is part of a broader circuit: T-bet (TBX21)³³ T-bet (TBX21)
the master Th1 transcription factor that drives IFN-gamma expression; T-bet promotes IFNG transcription and represses GATA-3-driven Th2 differentiation drives IFN-gamma production, and rs2069705 modulates how responsive the IFNG promoter is to T-bet-upstream signals including STAT4. Disruption at either node — reduced T-bet expression (rs4794067, TBX21 promoter variant) or reduced IFNG promoter responsiveness (rs2069705) — can depress Th1 output and increase Th2-driven atopic susceptibility.

The Evidence

The most direct evidence for the G allele's reduced IFN-gamma output comes from its association pattern across immune diseases. A 2023 Russian pediatric asthma study⁴⁴ 2023 Russian pediatric asthma study
Smolnikova et al. Vavilovskii Zhurnal Genet Selektsii 2023; 263 Russian children with asthma found that the coding TT genotype (plus-strand AA) was specifically associated with mild and controlled asthma phenotypes (p<0.05) — the Th1-competent A allele homozygotes showing the most favourable disease trajectory.

The clearest functional evidence comes from a 2024 mechanistic study in primary Sjögren's syndrome⁵⁵ 2024 mechanistic study in primary Sjögren's syndrome
Chen et al. Am J Physiol Cell Physiol 2024; luciferase reporter assays and chromatin immunoprecipitation demonstrating STAT4-IFNG promoter interaction which established the A allele as a transcriptional activator at this position.

At the related downstream SNP rs2430561 (+874T/A)⁶⁶ rs2430561 (+874T/A)
A nearby IFNG variant in partial LD with rs2069705, located in an NF-kappaB binding site at position +874 relative to the IFNG TSS, a 2009 Egyptian atopy study⁷⁷ 2009 Egyptian atopy study
Hussein et al. J Investig Allergol Clin Immunol 2009; Egyptian atopic patients vs healthy controls directly linked the low-producer IFNG allele to atopic disease: atopic patients showed a significantly higher frequency of the A allele at +874 (the low-producer allele at that position), with AA homozygotes showing decreased serum IFN-gamma, elevated total IgE, and increased eosinophil counts compared to TT homozygotes — a direct quantitative readout of how reduced IFN-gamma production enables Th2 immune activation.

At the gene interaction level, a 2016 SLE study⁸⁸ 2016 SLE study
Leng et al. Sci Rep 2016; 3,732 Chinese Han subjects identified a significant genetic interaction between rs2069705 (IFNG) and rs4794067 (TBX21 promoter) in SLE susceptibility — illustrating that this IFNG promoter variant does not act in isolation but as part of a coordinated T-bet/IFN-gamma regulatory axis.

Practical Implications

For GG homozygotes (coding CC, ~23% globally, ~11% of Europeans), the reduced IFNG promoter responsiveness creates the lowest baseline IFN-gamma output of the three genotypes. In the allergy-atopic context this translates to the most permissive environment for Th2-driven sensitisation: higher IgE class-switching potential, less Th1-mediated suppression of eosinophil recruitment, and increased susceptibility to sensitisation to environmental allergens. Strategies that actively support Th1 immune balance are most relevant for this group.

For AG heterozygotes (~50% globally), one G allele moderately reduces IFNG promoter responsiveness. The practical implications are milder, but the atopic tendency is real, and early attention to Th1-supporting exposures during immune development is appropriate.

AA homozygotes carry the population-common, Th1-competent genotype in most European and South Asian populations and are not at elevated atopic risk from this variant.

Interactions

The most clinically relevant interaction is between rs2069705 and rs4794067 (TBX21 promoter). TBX21 encodes T-bet, which drives IFN-gamma transcription; rs4794067-C reduces T-bet expression. Leng et al. (2016) found that while neither variant independently reached significance for SLE in their cohort, the combination was significant — suggesting that disruption at both the upstream driver (T-bet) and the downstream promoter (IFNG) produces compounded immune dysregulation exceeding either variant's individual effect. For the allergy-atopic category, carriers of both GG at rs2069705 and CC at rs4794067 face reduced IFN-gamma through two parallel mechanisms.

The nearby IFNG variant rs2430561⁹⁹ rs2430561
IFNG +874T/A, an NF-kappaB binding site variant extensively studied in atopic disease and autoimmunity is in partial LD with rs2069705 and likely captures overlapping variance in IFNG promoter activity.

Genotype Interpretations

What each possible genotype means for this variant:

AA “Th1-Competent Form” Normal

Common high-IFN-gamma genotype with robust Th1 immune balance

You carry two copies of the A allele at rs2069705 — the most common genotype in European (approximately 45%) and South Asian populations. The A allele (coding T) supports STAT4-driven IFN-gamma transcription, maintaining a robust Th1 immune tone that counterbalances Th2-mediated allergic responses. This genotype is not associated with elevated atopic susceptibility at this locus. About 27% of the global population shares this genotype, though it is substantially more common in European and South Asian ancestries.

AG “Partial Th1 Variant” Intermediate Caution

One G allele — moderately reduced IFNG promoter responsiveness and mildly elevated Th2 susceptibility

The GA genotype at rs2069705 reflects heterozygous disruption of STAT4 binding at the IFNG promoter. With one A allele retaining the STAT4 binding enhancement, IFN-gamma transcriptional capacity is partially maintained. The additive inheritance pattern means the effect scales with allele count: GA lies between AA (full Th1 capacity) and GG (most reduced capacity). The pediatric asthma study by Smolnikova et al. (2023) documented that the A allele genotype (AA = coding TT) was associated with mild and controlled asthma, implying that partial A allele presence (GA) supports intermediate disease control. Environmental Th2 triggers — early allergen sensitisation, antibiotic use disrupting microbiome Th1 programming, and reduced microbial diversity — compound the genetic susceptibility most in this genotype when other Th2-risk factors co-occur.

GG “Reduced Th1 Form” High Risk Warning

Homozygous G allele — lowest IFNG promoter responsiveness and highest Th2-skewing susceptibility at this locus

The GG genotype at rs2069705 represents homozygosity for the reduced-producer IFNG allele. Both copies of the promoter lack the STAT4-enhancing variation, meaning IFN-gamma transcription depends more heavily on other regulatory inputs (NF-kappaB, AP-1, SP1) without the STAT4 amplification. The functional consequence is a lower Th1 immune setpoint that makes the T-cell response more vulnerable to Th2 skewing in response to allergen exposures. Data from the related +874A/T variant (rs2430561) — where the low-producer allele directly correlates with decreased serum IFN-gamma, elevated IgE, and eosinophilia in atopic patients — illustrates the downstream consequences of reduced IFNG promoter activity on immune phenotype.

An important context: the G allele is the GRCh38 reference allele, but it is the biological minority in most Western populations and at a global allele frequency of ~41%. Being GG does not guarantee atopic disease — Th1/Th2 balance is influenced by dozens of loci, microbiome colonisation patterns, allergen exposure timing, and environmental factors. But among the IFNG promoter variants with functional evidence, GG confers the least genetically supported IFN-gamma output.